Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence

被引：0
作者：
Sara Nazha
Simon Tanguay
Anil Kapoor
Michael Jewett
Christian Kollmannsberger
Lori Wood
G. A. Georg Bjarnason
Daniel Heng
Denis Soulières
Martin Neil Reaume
Naveen Basappa
Eric Lévesque
Alice Dragomir
机构：
[1] McGill University Health Center,Sunnybrooke Hospital
[2] McMaster University,Tom Baker Cancer Center
[3] Princess Margaret Cancer Center,Centre Hospitalier de l’Université de Montréal
[4] University of British Columbia,Cross Cancer Institute
[5] Dalhousie University and Queen Elizabeth II Health Sciences Center,Centre Hospitalier Universitaire de Québec
[6] University of Toronto,Health Economics and Outcomes Research, Research Institute of the McGill University Health Center, Surgery/Urology
[7] University of Calgary,undefined
[8] University of Montreal,undefined
[9] University of Ottawa,undefined
[10] University of Alberta,undefined
[11] Université de Laval,undefined
[12] McGill University,undefined
来源：
Clinical Drug Investigation | 2018年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1155 / 1165
页数：10
相关论文
共 135 条
[1]  
Gupta K(2008)Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review Cancer Treat Rev 34 193-205
[2]  
Miller JD(2003)Metastatic renal cell carcinoma Curr Treat Opt Oncol 4 385-390
[3]  
Li JZ(2015)Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update Can Urol Assoc J 9 164-170
[4]  
Russell MW(2004)Genetic basis of cancer of the kidney: disease-specific approaches to therapy Clin Cancer Res 10 6282S-6289S
[5]  
Charbonneau C(2010)Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13 1-14
[6]  
Flanigan RC(2010)Molecular diagnosis and therapy of kidney cancer Annu Rev Med 61 329-343
[7]  
Campbell SC(2013)Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 722-731
[8]  
Clark JI(2017)First-line sunitinib or pazopanib in metastatic renal cell carcinoma: the Canadian experience Can Urol Assoc J 11 112-117
[9]  
Picken MM(2016)Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada Curr Oncol 23 e340-e354
[10]  
North SA(2015)Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States J Manag Care Spec Pharm 21 46-54, a–b
12345678910